500 related articles for article (PubMed ID: 16307682)
1. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
3. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR
Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
5. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
6. [Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema].
Carlavilla AB; López-Medrano F; Chaves F; Villena V; Echave-Sustaeta J; Aguado JM
Enferm Infecc Microbiol Clin; 2005 May; 23(5):270-3. PubMed ID: 15899177
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.
Kays MB; Smith DW; Wack ME; Denys GA
Pharmacotherapy; 2002 Mar; 22(3):395-9. PubMed ID: 11898897
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C
J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
[TBL] [Abstract][Full Text] [Related]
9. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Anderson KB; Tan JS; File TM; DiPersio JR; Willey BM; Low DE
Clin Infect Dis; 2003 Aug; 37(3):376-81. PubMed ID: 12884162
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
Urban C; Rahman N; Zhao X; Mariano N; Segal-Maurer S; Drlica K; Rahal JJ
J Infect Dis; 2001 Sep; 184(6):794-8. PubMed ID: 11517444
[TBL] [Abstract][Full Text] [Related]
11. Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation.
Kays MB; Zhanel GG; Reimann MA; Jacobi J; Denys GA; Smith DW; Wack MF
Pharmacotherapy; 2007 Feb; 27(2):221-6. PubMed ID: 17253913
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
Brown SD; Farrell DJ; Morrissey I
J Clin Microbiol; 2004 Nov; 42(11):4980-7. PubMed ID: 15528684
[TBL] [Abstract][Full Text] [Related]
14. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
Canton R; Morosini M; Enright MC; Morrissey I
J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
[TBL] [Abstract][Full Text] [Related]
15. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
16. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Iraurgui P; Torres MJ; Aznar J
Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
Sunagawa S; Fujita J; Higa F; Tateyama M; Haranaga S; Nakasone I; Yamane N; Uno T
J Antibiot (Tokyo); 2011 Aug; 64(8):539-45. PubMed ID: 21587266
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
20. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
